Evommune is a Biotech company based in Palo Alto. It has raised $115M in total funding. Latest round: Series C.
Evommune is a Biotech company based in Palo Alto. Evommune has raised $115M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series C announced in October 2024. The round record for Evommune runs through 2024; nothing later has been disclosed. Investors on record include RA Capital Management, Sectoral Asset Management, B Capital, Marshall Wace, Avego Bioscience Capital, Longwood Fund and 12 others. 18 distinct backers are named across the disclosed rounds.
Every Evommune figure above comes from filings and announced rounds in the StartupFundraising company database and is revised as new rounds are recorded. The lists below compare Biotech companies in Palo Alto at a similar stage.
Company funding database · Investor directory · Founder database · Mega-rounds 2026